Armata Pharmaceuticals (ARMP) Return on Capital Employed (2014 - 2026)
Armata Pharmaceuticals (ARMP) reported Return on Capital Employed of 58.07% for Q1 2026, down 22856.0% on a YoY basis from N/an in Q1 2025, and down 17.69% sequentially from 49.34% in Q4 2025.
Armata Pharmaceuticals (ARMP) Return on Capital Employed (2014 - 2026) Analysis & Trends
Armata Pharmaceuticals (ARMP) has 13 years of Return on Capital Employed data on file, last reported at 58.07% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed fell 22856.0% year-over-year to 58.07%; the trailing twelve-month figure through Mar 2026 stood at 58.07% (down 22856.0% YoY), and the FY2025 full-year result was 50.38%, up 4573.0% from the prior year.
- Return on Capital Employed fell to 58.07% in Q1 2026, from 49.34% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 5801.9% in Q1 2024 to a low of 96.26% in Q4 2024.
- A 5-year average of 369.42% and a median of 36.32% in 2022 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed jumped 587955 bps in 2024 and plunged 563141 bps in 2025, its largest moves.
- Tracing ARMP's Return on Capital Employed over 5 years: stood at 53.17% in 2022, then increased by 14 bps to 45.89% in 2023, then sank by 110 bps to 96.26% in 2024, then jumped by 49 bps to 49.34% in 2025, then slipped by 18 bps to 58.07% in 2026.
- Business Quant data shows ARMP's Return on Capital Employed at 58.07% in Q1 2026, 49.34% in Q4 2025, and 60.86% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Armata Pharmaceuticals | 191.29 Mn | 186.49 Mn | - | -58.07% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -58.07% |
| Dec 31, 2025 | -49.34% |
| Sep 30, 2025 | 60.86% |
| Jun 30, 2025 | 97.96% |
| Mar 31, 2025 | 170.49% |
| Dec 31, 2024 | -96.26% |
| Sep 30, 2024 | 277.83% |
| Jun 30, 2024 | 475.41% |
| Mar 31, 2024 | 5,801.90% |
| Dec 31, 2023 | -45.89% |
| Sep 30, 2023 | -48.93% |
| Jun 30, 2023 | -74.72% |
| Mar 31, 2023 | -77.65% |
| Dec 31, 2022 | -53.17% |
| Sep 30, 2022 | -36.32% |
| Jun 30, 2022 | -31.12% |
| Mar 31, 2022 | -32.91% |
| Dec 31, 2021 | -46.34% |
| Sep 30, 2021 | -60.23% |
| Jun 30, 2021 | -53.08% |